SG10201807034XA - A pharmaceutical composition for improving or preventing progression of Chronic Kidney Disease - Google Patents
A pharmaceutical composition for improving or preventing progression of Chronic Kidney DiseaseInfo
- Publication number
- SG10201807034XA SG10201807034XA SG10201807034XA SG10201807034XA SG10201807034XA SG 10201807034X A SG10201807034X A SG 10201807034XA SG 10201807034X A SG10201807034X A SG 10201807034XA SG 10201807034X A SG10201807034X A SG 10201807034XA SG 10201807034X A SG10201807034X A SG 10201807034XA
- Authority
- SG
- Singapore
- Prior art keywords
- improving
- pharmaceutical composition
- kidney disease
- chronic kidney
- preventing progression
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
A PHARMACEUTICAL COMPOSITION FOR IMPROVING OR PREVENTING PROGRESSION OF CHRONIC KIDNEY DISEASE 5 The present application relates to a pharmaceutical composition/formulation for improving or preventing progression of chronic kidney disease (CKD) caused due to inflammation and/or Klotho under expression. More particularly, the invention relates to a composition/formulation comprising a synergistic combination of Palmitoylethanolamide (PEA), Cholecalciferol and one or more natural ingredients. The invention also provides 10 various formulations and methods of preparing the same. [Figure 1] 15
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201721031443 | 2017-09-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201807034XA true SG10201807034XA (en) | 2019-04-29 |
Family
ID=63490286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201807034XA SG10201807034XA (en) | 2017-09-05 | 2018-08-20 | A pharmaceutical composition for improving or preventing progression of Chronic Kidney Disease |
Country Status (9)
Country | Link |
---|---|
US (1) | US10973782B2 (en) |
EP (1) | EP3449943B1 (en) |
BR (1) | BR102018067846A2 (en) |
CA (1) | CA3015399C (en) |
EA (1) | EA035709B1 (en) |
MY (1) | MY186286A (en) |
PH (1) | PH12018000227B1 (en) |
SG (1) | SG10201807034XA (en) |
UA (1) | UA123448C2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11523998B2 (en) | 2018-06-14 | 2022-12-13 | The Texas A&M University System | Anti-inflammatory formulations and uses thereof including a combination of palmitoylethanolamide and plant-based polyphenols |
WO2020141546A1 (en) * | 2019-01-02 | 2020-07-09 | Celagenex Research (India) Pvt. Ltd. | Synergistic nutritional compositions for pain management |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5506224A (en) | 1991-12-31 | 1996-04-09 | Lifegroup S.P.A. | N-acyl derivatives of aminoalcohols active as local autacoids and useful in the therapy of autoimmune processes |
IT1271266B (en) | 1994-12-14 | 1997-05-27 | Valle Francesco Della | THERAPEUTIC USE OF MONO AND BICARBOXYLIC ACID AMIDES WITH AMINO ALCOHOLS, SELECTIVELY ACTIVE ON THE PERIPHERAL RECEPTOR OF CANNABINOIDS |
CA2330681C (en) | 1998-05-29 | 2008-08-26 | Andrea Giuffrida | Control of pain with endogenous cannabinoids |
GB9923738D0 (en) | 1999-10-07 | 1999-12-08 | Nestle Sa | Nutritional composition |
AU2002338329B2 (en) | 2001-03-27 | 2006-09-07 | The Regents Of The University Of California | Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism |
EP1677780A4 (en) | 2003-10-16 | 2007-05-02 | Univ California | Dietary and other compositions, compounds, and methods for reducing body fat, controlling appetite, and modulating fatty acid metabolism |
ITPD20050224A1 (en) * | 2005-07-19 | 2007-01-20 | Actimex Srl | COMPOSITIONS CONTAINING MICRONUTRIENTS IN PARTICULAR ANTIOXIDANT ACTIVITY AND THEIR USE |
US20070207225A1 (en) * | 2006-03-03 | 2007-09-06 | Francesco Squadrito | Genistein modulated reduction of cardiovascular risk factors |
ATE464890T1 (en) | 2006-03-28 | 2010-05-15 | Epitech Group Srl | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PATHOLOGIES CAUSED BY THE GENERAL IMMUNE RESPONSE |
US8680053B2 (en) * | 2008-07-09 | 2014-03-25 | Quercegen Pharmaceuticals Llc | Improving renal function with quercetin-containing compositions |
BRPI0919183B8 (en) * | 2008-09-04 | 2021-05-25 | Cargill Inc | compressible composition of erythritol, process and use thereof |
PL2475352T5 (en) | 2009-09-07 | 2019-02-28 | Epitech Group S.P.A. | Composition containing ultra-micronized palmitoyl - ethanolamide |
US20120288573A1 (en) * | 2009-10-20 | 2012-11-15 | Herbonis Ag | Use of extracts from salonum glaucophyllum for treating bone metabolism disorders and kidney disorders |
US9187413B2 (en) | 2010-07-28 | 2015-11-17 | The Regents Of The University Of California | Peripherally restricted FAAH inhibitors |
ES2648051T3 (en) * | 2010-10-04 | 2017-12-28 | Epitech Group S.P.A. | Use of mono and dicarboxylic acid amides in the treatment of kidney diseases |
MX354772B (en) | 2011-08-19 | 2018-03-21 | Univ California | Meta-substituted biphenyl peripherally restricted faah inhibitors. |
US20130085121A1 (en) * | 2011-09-30 | 2013-04-04 | Jianguo Wang | Pharmaceutical compositions comprising phosphate binder, calcium receptor-active compound and/or active vitamin d |
US9512091B2 (en) * | 2012-02-17 | 2016-12-06 | Epitech Group S.R.L. | Compositions and methods for the modulation of specific amidases for N-acylethanolamines for use in the therapy of inflammatory diseases |
WO2014004676A1 (en) * | 2012-06-26 | 2014-01-03 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors as neuroprotective agents in the cns |
PL2890684T3 (en) | 2012-07-24 | 2018-08-31 | Bial-Portela & Ca, S.A. | Urea compounds and their use as enzyme inhibitors |
NL2011448C2 (en) | 2012-09-17 | 2015-01-29 | Jp Russell Science Holding Ltd | Pharmaceutical or neutraceutical composition comprising palmitoylethanolamide particles. |
WO2014202956A1 (en) * | 2013-06-21 | 2014-12-24 | Noakes, David | Vitamin d complexes with de-vdbp and an unsaturated fatty acid, and their use in therapy |
ITMI20131180A1 (en) | 2013-07-15 | 2015-01-16 | Fond Istituto Italiano Di Tecnologia | O-ALCHIL TRIAZOLYL CARBAMMATES AS INHIBITORS OF HYDROLASIS OF AMIDIDES OF FATTY ACIDS (FAAH) |
RU2693457C2 (en) | 2013-07-18 | 2019-07-03 | Фондацьоне Иституто Итальяно Ди Текнолоджия | Phenylcarbamates and use thereof as enzyme inhibitors of hydrolases of fatty acid amides (faah) and dopamine receptor d3 (d3dr) modulators |
CN105793247B (en) | 2013-07-24 | 2018-03-16 | 比亚尔-珀特拉和Ca股份公司 | Imidazole carboxamides and its purposes as FAAH inhibitor |
BR112016002196A2 (en) | 2013-08-01 | 2017-08-01 | BIAL PORTELA & Cª S A | urea compounds and their use as enzyme inhibitors |
EP2921167B1 (en) * | 2014-03-19 | 2016-08-17 | EPITECH GROUP S.p.A. | Pharmaceutical composition comprising palmitoylethanolamide and l-acetylcarnitine |
EP3988540A1 (en) | 2014-04-07 | 2022-04-27 | The Regents of the University of California | Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments |
ES2731729T3 (en) | 2014-05-14 | 2019-11-18 | Epitech Group S P A | Use of palmitoylethanolamide in combination with opioids |
US10646523B2 (en) | 2014-10-22 | 2020-05-12 | Again Life Italia Srl | Combination comprising spirulina and palmitoylethanolamide and/or salts or pharmaceutically acceptable derivatives thereof and their formulations, for use in the prevention and/or in the treatment of hyperactivated tissue conditions |
NL2014464B1 (en) | 2015-03-16 | 2017-01-13 | Vanderbilt Science Holding Ltd | Composition for use in the treatment of neuropathic pain. |
WO2016183134A1 (en) | 2015-05-12 | 2016-11-17 | Cutting Edge Medical Solutions, Llc | Palmitoylethanolamide compositions |
US20180116982A1 (en) | 2015-05-21 | 2018-05-03 | Therapix Biosciences Ltd. | Combinations of opioids and n-acylethanolamines |
US10350179B2 (en) | 2015-06-04 | 2019-07-16 | Raffaele Migliaccio | Combination comprising palmitoylethanolamide (PEA) and lycopene for use in the treatment of inflammatory diseases |
ITUB20153066A1 (en) * | 2015-08-11 | 2017-02-11 | Graal S R L | FOOD AND / OR NUTRACEUTICAL COMPOSITION CONTAINING PEA |
-
2018
- 2018-08-20 PH PH12018000227A patent/PH12018000227B1/en unknown
- 2018-08-20 SG SG10201807034XA patent/SG10201807034XA/en unknown
- 2018-08-20 MY MYPI2018702932A patent/MY186286A/en unknown
- 2018-08-22 US US16/108,947 patent/US10973782B2/en active Active
- 2018-08-27 CA CA3015399A patent/CA3015399C/en active Active
- 2018-08-31 EA EA201891752A patent/EA035709B1/en unknown
- 2018-09-03 UA UAA201809082A patent/UA123448C2/en unknown
- 2018-09-03 EP EP18192176.8A patent/EP3449943B1/en active Active
- 2018-09-04 BR BR102018067846-9A patent/BR102018067846A2/en active Search and Examination
Also Published As
Publication number | Publication date |
---|---|
EA035709B1 (en) | 2020-07-29 |
US10973782B2 (en) | 2021-04-13 |
PH12018000227A1 (en) | 2019-03-11 |
US20190070133A1 (en) | 2019-03-07 |
EA201891752A2 (en) | 2019-03-29 |
PH12018000227B1 (en) | 2019-03-11 |
EA201891752A3 (en) | 2019-05-31 |
EP3449943A1 (en) | 2019-03-06 |
CA3015399A1 (en) | 2019-03-05 |
BR102018067846A2 (en) | 2020-07-07 |
MY186286A (en) | 2021-07-05 |
UA123448C2 (en) | 2021-04-07 |
EP3449943B1 (en) | 2022-08-31 |
CA3015399C (en) | 2020-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY202018A (en) | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies | |
PH12020550051A1 (en) | Glp-1 compositions and uses thereof | |
MX2017015879A (en) | Hydroxypropyl beta-cyclodextrin compositions and methods. | |
AR104835A1 (en) | NUTRITIONAL COMPOSITIONS CONTAINING A HIGH LEVEL OF INOSITOL AND USE OF THE SAME | |
BR112017017448A2 (en) | Methods and Compositions for the Treatment of Resected Eye Disease and Other Eye Disorders | |
MX2017011830A (en) | Phytocomplexes exhibiting multiple, synergistic antioxidant activities useful in foods, dietary supplements, cosmetics and pharmaceutical preparations. | |
MX2020006612A (en) | Compound functioning as bromodomain protein inhibitor, and composition. | |
MX2016014281A (en) | Natural combination hormone replacement formulations and therapies. | |
PH12019550263A1 (en) | A Pharmaceutical Composition for Anaemia | |
BR112021019262A2 (en) | Use of cyclo-his-pro (chp) to prevent, mitigate or treat fibrosis | |
BR112017009510A2 (en) | compositions comprising cyclosporine | |
PH12017502322A1 (en) | Therapeutic agent for fibrosis | |
PH12021550705A1 (en) | Stable semaglutide compositions and uses thereof | |
MX2019009952A (en) | Low-viscosity, high-concentration evolocumab formulations and methods of making the same. | |
CR20220355A (en) | Compounds active towards nuclear receptors | |
MX2022007265A (en) | Compounds active towards nuclear receptors. | |
SG10201807034XA (en) | A pharmaceutical composition for improving or preventing progression of Chronic Kidney Disease | |
CY1122829T1 (en) | PHARMACEUTICAL COMPOSITION FOR NEUROPATHIC PAIN | |
MX2020007760A (en) | Compositions and methods of enhancing 5-hydroxytryptophan bioavailability. | |
PH12019501820A1 (en) | Pharmaceutical compositions for combination therapy | |
MX2017013879A (en) | Compositions comprising anakinra. | |
EP3829643C0 (en) | Synergistically cooperative compositions useful for soft tissue augmentation, drug delivery and related fields | |
MX2019006513A (en) | Natural combination hormone replacement formulations and therapies. | |
WO2015126151A3 (en) | Composition for wound healing comprising massa medicata fermentata extract | |
MX2023005681A (en) | Pharmaceutical composition for treating acute and chronic pain, containing polmacoxib and tramadol. |